tiprankstipranks
Trending News
More News >

Recursion Pharmaceuticals Holds Annual Stockholder Meeting

Story Highlights
Recursion Pharmaceuticals Holds Annual Stockholder Meeting

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Recursion Pharmaceuticals ( (RXRX) ).

On June 18, 2025, Recursion Pharmaceuticals held its annual meeting of stockholders where key proposals were voted on. Stockholders elected three Class I directors to serve until 2028, approved the executive compensation plan, and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025. These decisions are expected to influence the company’s governance and financial oversight in the coming years.

The most recent analyst rating on (RXRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.

Spark’s Take on RXRX Stock

According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.

Recursion Pharmaceuticals shows promise with strong revenue growth and strategic partnerships, but faces significant challenges with profitability and operational efficiency. Technical indicators suggest potential downward momentum, and the negative P/E ratio highlights valuation concerns. Despite these challenges, recent corporate actions and a strategic focus on high-potential projects provide a cautiously optimistic outlook.

To see Spark’s full report on RXRX stock, click here.

More about Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on leveraging advanced computational techniques to accelerate drug discovery and development.

Average Trading Volume: 23,346,625

Technical Sentiment Signal: Sell

Current Market Cap: $2.03B

Find detailed analytics on RXRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1